|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/18 Actinium Pharmaceuticals, Inc. 10-Q 9/30/18 44:2.4M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 324K
2: EX-4.1 Amendment to Actinium Pharmaceuticals, Inc. HTML 17K
Warrant to Purchase Common Stock, Dated November
8, 2018 Issued to Amosan LLC.
3: EX-4.2 Amendment to Actinium Pharmaceuticals, Inc. HTML 17K
Warrant to Purchase Common Stock, Dated November
8, 2018 Issued to Carnegie Hill Partners
4: EX-4.3 Amendment to Actinium Pharmaceuticals, Inc. HTML 17K
Warrant to Purchase Common Stock, Dated November
8, 2018 Issued to Bioche Asset Management, LLC.
5: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
15: R1 Document and Entity Information HTML 42K
16: R2 Consolidated Balance Sheets (Unaudited) HTML 79K
17: R3 Consolidated Balance Sheets (Unaudited) HTML 37K
(Parenthetical)
18: R4 Consolidated Statements of Operations (Unaudited) HTML 53K
19: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 63K
20: R6 Description of Business and Summary of Significant HTML 58K
Accounting Policies
21: R7 Derivative Liabilities HTML 35K
22: R8 Commitments and Contingencies HTML 29K
23: R9 Equity HTML 46K
24: R10 Supplemental Disclosure of Cash Flow Information HTML 17K
25: R11 Subsequent Events HTML 26K
26: R12 Description of Business and Summary of Significant HTML 88K
Accounting Policies (Policies)
27: R13 Description of Business and Summary of Significant HTML 33K
Accounting Policies (Tables)
28: R14 Derivative Liabilities (Tables) HTML 35K
29: R15 Equity (Tables) HTML 35K
30: R16 Description of Business and Summary of Significant HTML 23K
Accounting Policies (Details)
31: R17 Description of Business and Summary of Significant HTML 19K
Accounting Policies (Details 1)
32: R18 Description of Business and Summary of Significant HTML 29K
Accounting Policies (Details 2)
33: R19 Description of Business and Summary of Significant HTML 32K
Accounting Policies (Details Textual)
34: R20 Derivative Liabilities (Details) HTML 22K
35: R21 Derivative Liabilities (Details 1) HTML 36K
36: R22 Derivative Liabilities (Details Textual) HTML 30K
37: R23 Commitments and Contingencies (Details) HTML 46K
38: R24 Equity (Details) HTML 54K
39: R25 Equity (Details 1) HTML 63K
40: R26 Equity (Details Textual) HTML 100K
41: R27 Subsequent Events (Details) HTML 53K
43: XML IDEA XML File -- Filing Summary XML 68K
42: EXCEL IDEA Workbook of Financial Reports XLSX 37K
9: EX-101.INS XBRL Instance -- atnm-20180930 XML 503K
11: EX-101.CAL XBRL Calculations -- atnm-20180930_cal XML 82K
12: EX-101.DEF XBRL Definitions -- atnm-20180930_def XML 324K
13: EX-101.LAB XBRL Labels -- atnm-20180930_lab XML 569K
14: EX-101.PRE XBRL Presentations -- atnm-20180930_pre XML 449K
10: EX-101.SCH XBRL Schema -- atnm-20180930 XSD 93K
44: ZIP XBRL Zipped Folder -- 0001213900-18-015315-xbrl Zip 72K
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Actinium Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sandesh Seth, Chairman & CEO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Date: November 9, 2018 | By: | /s/ Sandesh Seth |
| Sandesh Seth | ||
|
Chairman & CEO (Duly Authorized Officer and Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/9/18 | None on these Dates | ||
| For Period end: | 9/30/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/22 Actinium Pharmaceuticals, Inc. 10-K 12/31/21 56:4.2M EdgarAgents LLC/FA 3/31/21 Actinium Pharmaceuticals, Inc. 10-K 12/31/20 56:3.5M EdgarAgents LLC/FA |